GlaxoSmithKline and CureVac N.V. entered new €150 million collaboration to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine.   GSK will support the manufacture of up to 100 million doses of CureVac’s first generation COVID-19 vaccine candidate CVnCoV in 2021.   Through this new co-development agreement, the companies will contribute resources and expertise to research, develop, and m...